Comparative Forced Degradation Study of Anticomplement C5 Biosimilar and Originator Monoclonal Antibodies
<b>Background/Objectives</b>: The stress testing of biotherapeutic products is a critical component of drug development, enabling the assessment of stability, biosimilarity, and degradation pathways. Subjecting biosimilar monoclonal antibodies to controlled stress conditions yields essen...
Saved in:
| Main Authors: | Merve Celik Yamaci, Ceren Pamukcu, Yigit Erdemgil, Ahmet Emin Atik, Zeynep Zulfiye Yildirim Keles, Ozge Can |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/4/579 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Studying the pharmacokinetics of biotechnological medicinal products on the example of monoclonal antibodies
by: V. V. Smirnov, et al.
Published: (2023-06-01) -
The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma
by: Léon Raymakers, et al.
Published: (2025-04-01) -
Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia
by: A. Yu. Efremov, et al.
Published: (2025-05-01) -
International standards for monoclonal antibodies for assessing the biological activity of medicines: A status update
by: L. A. Gayderova, et al.
Published: (2023-12-01) -
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies
by: Gao-Yuan Liu, et al.
Published: (2025-12-01)